Sarepta Therapeutics, Inc. (SRPT) stock
Close on Nov 13, 2026Market cap $1.70BP/E –Yield –
Earnings
Sarepta Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Sarepta Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 24, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $381.40M | -4.5% | -$0.27 | $0.13 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026during market hours | $401.30M | -21.8% | -$0.05 | $0.64 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026during market hours | $730.80M | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026during market hours | $442.90M | -32.7% | -$3.93 | -$3.58 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 3, 2025during market hours | $399.40M | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 16, 2025during market hours | $513.00M | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 26, 2025during market hours | $658.40M | – | $1.50 | $1.90 | Release |
| Q4 FY2023ended Dec 31, 2023 | Jan 8, 2024before the open | – | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Jan 9, 2023before the open | $235.50M | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Jan 10, 2022before the open | – | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 15, 2021during market hours | $166.90M | – | – | – | Release |
| Q4 FY2020ended Dec 31, 2020 | Jan 11, 2021before the open | – | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Jan 13, 2020before the open | – | – | – | – | Filing |
| Q4 FY2018ended Dec 31, 2018 | Feb 27, 2019during market hours | – | – | – | – | Filing |
| Q4 FY2017ended Dec 31, 2017 | Jan 8, 2018before the open | – | – | – | – | Filing |
| Q2 FY2017ended Jun 30, 2017 | Jul 19, 2017during market hours | – | – | – | – | Filing |
| Q1 FY2017ended Mar 31, 2017 | Apr 27, 2017during market hours | – | – | – | – | Filing |
| Q4 FY2016ended Dec 31, 2016 | Feb 28, 2017during market hours | – | – | – | – | Filing |
| Q3 FY2016ended Sep 30, 2016 | Oct 27, 2016before the open | – | – | – | – | Filing |
| Q2 FY2016ended Jun 30, 2016 | Jul 19, 2016during market hours | – | – | – | – | Filing |
| Q1 FY2016ended Mar 31, 2016 | May 5, 2016before the open | – | – | – | – | Filing |
| Q4 FY2015ended Dec 31, 2015 | Feb 25, 2016during market hours | – | – | – | – | Filing |
| Q3 FY2015ended Sep 30, 2015 | Oct 6, 2015during market hours | – | – | – | – | Filing |
| Q2 FY2015ended Jun 30, 2015 | Aug 6, 2015before the open | – | – | – | – | Filing |
| Q1 FY2015ended Mar 31, 2015 | May 7, 2015before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Sarepta Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| total net product revenue | FY2026 | $1.25B – $1.30B | – | New | Nov 5, 2026 |
| total net product revenue | FY2026 | $1.20B – $1.30B | $1.20B – $1.40B | Lowered | Aug 5, 2026 |
| average annual non-GAAP R&D and SG&A expensesnon-GAAP | FY2026 | $800.00M – $900.00M | – | New | Jul 16, 2025 |
| combined non-GAAP R&D and SG&A expensenon-GAAP | FY2026 | $800.00M – $850.00M | – | Lowered | Aug 5, 2026 |
| combined non-GAAP R&D and SG&A expensesnon-GAAP | FY2026 | $800.00M – $825.00M | – | Lowered | Nov 5, 2026 |
| combined non-GAAP R&D and SG&A expensesnon-GAAP | FY2026 | $800.00M – $900.00M | – | New | May 6, 2026 |
Guidance history
Every forecast Sarepta Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | combined non-GAAP R&D and SG&A expenses | FY2026 | $800.00M – $825.00M | Lowered |
| Nov 5, 2026 | total net product revenue | FY2026 | $1.25B – $1.30B | New |
| Aug 5, 2026 | combined non-GAAP R&D and SG&A expense | FY2026 | $800.00M – $850.00M | Lowered |
| Aug 5, 2026 | total net product revenue | FY2026 | $1.20B – $1.30B | Lowered |
| May 6, 2026 | combined non-GAAP R&D and SG&A expenses | FY2026 | $800.00M – $900.00M | New |
| May 6, 2026 | Total net product revenues | FY2026 | $1.20B – $1.40B | New |
| Jul 16, 2025 | average annual non-GAAP R&D and SG&A expenses | FY2026 | $800.00M – $900.00M | New |
| Jan 13, 2025 | total net product revenue | FY2025 | $2.90B – $3.10B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Sarepta Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Results
- News
- Results
- Results
- Results
- Results
- Results
- Update
- Update
- Results
See a number that looks wrong?